Bioceres Crop Solutions Statistics

Total Valuation

BCBA:BIOX has a market cap or net worth of ARS 334.35 billion. The enterprise value is 655.51 billion.

Market Cap	334.35B
Enterprise Value	655.51B

Important Dates

The next estimated earnings date is Monday, September 8, 2025.

Earnings Date	Sep 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-4.77%
Shares Change (QoQ)	-0.61%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	35.20M

Valuation Ratios

PE Ratio	n/a
Forward PE	36.75
PS Ratio	0.81
PB Ratio	0.90
P/TBV Ratio	21.53
P/FCF Ratio	7.95
P/OCF Ratio	6.72
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.53, with an EV/FCF ratio of 15.60.

EV / Earnings	-67.42
EV / Sales	1.44
EV / EBITDA	12.53
EV / EBIT	26.66
EV / FCF	15.60

Financial Position

The company has a current ratio of 1.02, with a Debt / Equity ratio of 0.79.

Current Ratio	1.02
Quick Ratio	0.72
Debt / Equity	0.79
Debt / EBITDA	5.99
Debt / FCF	6.98
Interest Coverage	0.87

Financial Efficiency

Return on equity (ROE) is -2.67% and return on invested capital (ROIC) is 2.28%.

Return on Equity (ROE)	-2.67%
Return on Assets (ROA)	1.70%
Return on Invested Capital (ROIC)	2.28%
Return on Capital Employed (ROCE)	4.78%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.47
Inventory Turnover	2.08

Taxes

Income Tax	-10.19B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -63.72% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-63.72%
50-Day Moving Average	5,418.80
200-Day Moving Average	7,220.20
Relative Strength Index (RSI)	45.75
Average Volume (20 Days)	51,380

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.33

Income Statement

In the last 12 months, BCBA:BIOX had revenue of ARS 411.31 billion and -9.72 billion in losses. Loss per share was -154.82.

Revenue	411.31B
Gross Profit	160.78B
Operating Income	23.92B
Pretax Income	-20.14B
Net Income	-9.72B
EBITDA	43.86B
EBIT	23.92B
Loss Per Share	-154.82

Full Income Statement

Balance Sheet

The company has 42.22 billion in cash and 293.28 billion in debt, giving a net cash position of -251.06 billion.

Cash & Cash Equivalents	42.22B
Total Debt	293.28B
Net Cash	-251.06B
Net Cash Per Share	n/a
Equity (Book Value)	370.19B
Book Value Per Share	5,278.12
Working Capital	6.33B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 49.79 billion and capital expenditures -7.76 billion, giving a free cash flow of 42.03 billion.

Operating Cash Flow	49.79B
Capital Expenditures	-7.76B
Free Cash Flow	42.03B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 39.09%, with operating and profit margins of 5.82% and -2.36%.

Gross Margin	39.09%
Operating Margin	5.82%
Pretax Margin	-4.90%
Profit Margin	-2.36%
EBITDA Margin	10.66%
EBIT Margin	5.82%
FCF Margin	10.22%

Dividends & Yields

BCBA:BIOX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	4.77%
Shareholder Yield	n/a
Earnings Yield	-2.91%
FCF Yield	12.57%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on January 24, 2024. It was a forward split with a ratio of 2.

Last Split Date	Jan 24, 2024
Split Type	Forward
Split Ratio	2

Scores

BCBA:BIOX has an Altman Z-Score of 1.26 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.26
Piotroski F-Score	5